p53 overexpression and mutation, chemoresistance and patient survival in oral and maxillofacial squamous cell carcinoma.
Cutilli
T
T
Dept. of Surgery, University of L'Aquila, Aquila, Italy.
Papola
F
F
Corbacelli
A
A
D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000378:metabolism* / Q000401:mortality / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000627:therapeutic use; D004273:DNA, Neoplasm / Q000032:analysis; D019008:Drug Resistance, Neoplasm; D005153:Facial Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000628:therapy; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D015870:Gene Expression; D006801:Humans; D008297:Male; D008441:Maxillary Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000628:therapy; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000628:therapy; D009154:Mutation; D016133:Polymerase Chain Reaction; D011379:Prognosis; D015996:Survival Rate; D016159:Tumor Suppressor Protein p53 / Q000096:biosynthesis* / Q000235:genetics
D000964:Antimetabolites, Antineoplastic; D004273:DNA, Neoplasm; D016159:Tumor Suppressor Protein p53; D002945:Cisplatin; D005472:Fluorouracil